Additionally, the low frequency of KRAS mutation or BRAF mutations in type II ovarian carcinomas in the current and previous studies suggest that p-ERK expression may be affected by the other receptor tyrosine kinase regulation mechanisms (i.e., EGFR, Her2, etc.) [8,14,15]. This evidence concerns the gene NTRK1 and ovarian carcinoma.